These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3387499)

  • 41. Pretreatment plasma HVA and haloperidol response in acute mania.
    Chou JC; Czobor P; Tuma I; Charles O; Bebe R; Cooper TB; Chang WH; Lane HY; Stone DL
    J Affect Disord; 2000 Jul; 59(1):55-9. PubMed ID: 10814771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
    Davila R; Gonzalez MA; Zumarraga M; Andia I; Guimon J; Silva RR; Friedhoff AJ
    Biol Psychiatry; 1995 Aug; 38(4):267-9. PubMed ID: 8547450
    [No Abstract]   [Full Text] [Related]  

  • 43. Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
    Amin F; Davidson M; Kahn RS; Schmeidler J; Stern R; Knott PJ; Apter S
    Schizophr Bull; 1995; 21(1):53-66. PubMed ID: 7770741
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in guinea pigs.
    Chang WH; Jaw SS; Wu HS; Tsay L; Yeh EK
    Psychopharmacology (Berl); 1988; 96(3):285-8. PubMed ID: 3146762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
    Csernansky JG; Newcomer JW; Jackson K; Lombrozo L; Faull KF; Zipursky R; Pfefferbaum A; Faustman WO
    Psychopharmacology (Berl); 1994 Nov; 116(3):291-6. PubMed ID: 7534423
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pretreatment plasma HVA predicts neuroleptic response in manic psychosis.
    Mazure CM; Bowers MB
    J Affect Disord; 1998 Feb; 48(1):83-6. PubMed ID: 9495606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
    Bowers MB; Mazure CM; Nelson JC; Jatlow PI
    Biol Psychiatry; 1992 Dec; 32(12):1102-7. PubMed ID: 1477190
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum homovanillic acid levels in schizophrenic patients and normal control subjects.
    Steinberg JL; Garver DL; Moeller FG; Raese JD; Orsulak PJ
    Psychiatry Res; 1993 Aug; 48(2):93-106. PubMed ID: 8416025
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Plasma and CSF HVA before and after pharmacological treatment.
    Sharma R; Javaid JI; Janicak P; Faull K; Comaty J; Davis JM
    Psychiatry Res; 1989 Apr; 28(1):97-104. PubMed ID: 2740469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
    Kelley ME; Yao JK; van Kammen DP
    Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
    Baeza I; Castro-Fornieles J; Deulofeu R; de la Serna E; Goti J; Salvà J; Bernardo M
    Psychiatry Res; 2009 Jul; 168(2):110-8. PubMed ID: 19501918
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plasma HVA, neuroleptics, and dopaminergic plasticity.
    Dávila R
    Biol Psychiatry; 1989 Jan; 25(1):1-3. PubMed ID: 2563229
    [No Abstract]   [Full Text] [Related]  

  • 54. Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.
    Watanabe K; Miura I; Kanno-Nozaki K; Horikoshi S; Mashiko H; Niwa S; Yabe H
    Psychiatry Res; 2015 Dec; 230(2):419-23. PubMed ID: 26416588
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
    Arrúe A; Dávila R; Zumárraga M; Basterreche N; González-Torres MA; Goienetxea B; Zamalloa MI; Anguiano JB; Guimón J
    Neurochem Res; 2010 Feb; 35(2):247-53. PubMed ID: 19701707
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma homovanillic acid and prognosis in schizophrenia.
    Baker NJ; Kirch DG; Waldo M; Bell J; Adler LE; Hattox S; Murphy R; Freedman R
    Biol Psychiatry; 1991 Jan; 29(2):192-6. PubMed ID: 1671646
    [No Abstract]   [Full Text] [Related]  

  • 57. Plasma HVA in psychiatric patients: longitudinal studies.
    Javaid JI; Sharma RP; Janicak PG; Davis JM
    Psychopharmacol Bull; 1990; 26(3):361-5. PubMed ID: 2274637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D; Labarca R; Linnoila M; Roy A; Hommer D; Everett D; Paul SM
    Science; 1984 Aug; 225(4665):954-7. PubMed ID: 6474162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia.
    Ribeyre JM; Lesieur P; Varoquaux O; Dollfus S; Pays M; Petit M
    Biol Psychiatry; 1994 Aug; 36(4):230-6. PubMed ID: 7986887
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration.
    Davidson M; Giordani AB; Mohs RC; Horvath TB; Davis BM; Powchik P; Davis KL
    Arch Gen Psychiatry; 1987 Feb; 44(2):189-90. PubMed ID: 3813816
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.